Tag: immunotherapy resistance
-
Kazia Therapeutics Unveils Compelling NDL2 Data on Nuclear PD-L1 Driving Immunotherapy Resistance
Kazia Therapeutics Reveals Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics, a leader in oncology-focused drug development, announced new preclinical and translational data supporting the potential of its Nuclear PD-L1 Degrader 2 (NDL2). The data illuminate nuclear PD-L1 as a previously underappreciated driver of immunotherapy resistance and metastatic progression, offering a…
-
Understanding Immunotherapy Resistance in Kidney Cancer: The Role of Myeloid Cell Signaling
Overview: A New Mechanism Driving Immunotherapy Resistance in Kidney Cancer Immunotherapy has transformed the treatment landscape for advanced renal cell carcinoma (RCC), offering durable responses for some patients. Yet a significant proportion of individuals experience resistance, limiting the long-term effectiveness of immune-based therapies. A landmark study published in Immunity in October 2025 identifies a key…
-
Myeloid-Driven Immunotherapy Resistance in Kidney Cancer: Interferon Signaling Under Scrutiny
Overview: A New Mechanism Behind Immunotherapy Resistance in Kidney Cancer Immunotherapy has transformed the treatment landscape for advanced renal cell carcinoma (RCC), but responses remain inconsistent. A landmark study published in Immunity (October 2025) by researchers including Dana-Farber Cancer Institute’s Eliezer M. Van Allen, MD, identifies a critical role for myeloid cells in shaping resistance…